Terms used in this chapter mean:
(1)"Biological product," as defined in 42 U.S.C. § 262(i), (January 1, 2018); (2)"Board," the State Board of Pharmacy;
(3)"Brand name," the proprietary or registered trademark name given to a drug product by its manufacturer, labeler, or distributor and placed on the drug or on its container, label, or wrapping at the time of packaging;
(4)"Compounding," the preparation, mixing, assembling, packaging, or labeling of a drug or drug device as the result of a practitioner's prescription drug order or an initiative based on the pharmacist/patient/practitioner relationship in the course of professional practice or for the purpose of or as an incident to research, teaching, or chemical analysis and not for sale or dispensing. The term also include
Free access — add to your briefcase to read the full text and ask questions with AI
Terms used in this chapter mean: (1) "Biological product," as defined in 42 U.S.C. § 262(i), (January 1, 2018); (2) "Board," the State Board of Pharmacy; (3) "Brand name," the proprietary or registered trademark name given to a drug product by its manufacturer, labeler, or distributor and placed on the drug or on its container, label, or wrapping at the time of packaging; (4) "Compounding," the preparation, mixing, assembling, packaging, or labeling of a drug or drug device as the result of a practitioner's prescription drug order or an initiative based on the pharmacist/patient/practitioner relationship in the course of professional practice or for the purpose of or as an incident to research, teaching, or chemical analysis and not for sale or dispensing. The term also includes the preparation of drug or drug devices in anticipation of prescription drug orders based on routine, regularly observed prescribing patterns; (5) "Delivery," the actual, constructive, or attempted transfer of a drug or drug device from one person to another, whether or not for a consideration; (6) "Dispensing," the preparation and delivery of a drug to a patient or a patient's agent pursuant to a prescription drug order in a suitable container with appropriate labeling for subsequent administration to or use by a patient. The term includes preparation of labels for drug devices if the labeling is related to the dosage and administration of drugs; (7) "Distributing," the delivery of a drug or drug device other than by administration or dispensing; (8) "Drug administration," the direct application of a drug or drug device by injection, inhalation, ingestion, or any other means to the body of a patient or research subject; (9) "Drug device," equipment, process, biotechnological entity, diagnostic agent, or other product used in combination with a drug to provide effective management of medication regimens; (10) "Equivalent drug product," a drug product, other than a biological product, that is considered to be therapeutically equivalent to other pharmaceutically equivalent products as determined by the edition of Approved Drug Products with Therapeutic Equivalence Evaluations adopted by the board through rules promulgated pursuant to chapter 1-26 ; (11) "Interchangeable biological product," a biological product that the United States Food and Drug Administration either has licensed and determined meets the standards for interchangeability pursuant to 42 U.S.C. § 262(k)(4), (January 1, 2018), or has determined is therapeutically equivalent, as set forth in the edition of Approved Drug Products with Therapeutic Equivalence Evaluations as adopted by the board through rules promulgated pursuant to chapter 1-26 ; (12) "Labeling," the process of preparing and affixing a label to any drug or drug device container exclusive of the labeling by the manufacturer, packer, or distributor of a nonprescription drug or commercially packaged legend drug or drug device; (13) "Medicines," drugs or chemicals, or their preparations, in suitable form for the prevention, relief, or cure of diseases when used either internally or externally by man or for animals; (14) "Nonprescription drugs," drugs that are labeled for use by the general public in accordance with 21 U.S.C. § 352 (January 1, 2025), and may be sold without a prescription drug order in accordance with 21 U.S.C. § 353 (January 1, 2025). The term does not include drugs that are required by federal law to bear the statement "Caution: federal law prohibits dispensing without prescription," drugs intended for human use by hypodermic injection, or animal remedies regulated by chapter 39-18 ; (15) "Patient counseling," oral communication by the pharmacist of information to the patient or caregiver to improve therapy by ensuring proper use of drugs and drug devices; (16) "Pharmaceutical care," provision of drug therapy and other pharmaceutical patient care services intended to achieve outcomes related to curing or preventing a disease, eliminating or reducing a patient's symptoms, or arresting or slowing a disease process; (17) "Pharmacist," a person licensed by the board to engage in the practice of pharmacy; (18) "Pharmacy," any place of business within or outside this state where drugs are dispensed and pharmaceutical care is provided to residents of this state; (19) "Practitioner," a person licensed, registered, or otherwise authorized by the jurisdiction in which the person is practicing to prescribe drugs in the course of professional practice; (20) "Prescription drug order," a written or oral order of a practitioner for a drug or drug device for a specific patient; (21) "Proper name," the nonproprietary name for a biological product designated by the United States Food and Drug Administration license for use upon each package of the product; and (22) "Registered pharmacy technician," a person registered by the board who is employed by a pharmacy to assist pharmacists in the practice of pharmacy by performing specific tasks delegated by and under the immediate personal supervision and control of a pharmacist, as permitted by the board.